Detalhe da pesquisa
1.
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.
Oncologist
; 24(6): 857-863, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30126857
2.
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
Cancer
; 124(1): 105-109, 2018 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28940498
3.
Malignant peripheral nerve sheath tumors.
Oncologist
; 19(2): 193-201, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24470531
4.
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
J Thorac Oncol
; 18(4): 516-526, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36240971
5.
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.
Clin Cancer Res
; 29(8): 1423-1428, 2023 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729110
6.
Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer.
Clin J Oncol Nurs
; 26(5): 543-551, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108212
7.
Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas.
Nat Commun
; 13(1): 6095, 2022 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36241629
8.
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations.
JTO Clin Res Rep
; 3(1): 100256, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34984405
9.
Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor.
JCO Precis Oncol
; 52021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34250388
10.
Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib.
JCO Precis Oncol
; 52021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34250398
11.
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers.
Clin Cancer Res
; 26(8): 1796-1802, 2020 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31919132
12.
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
JAMA Oncol
; 6(7): 1048-1054, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32463456
13.
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers.
Cold Spring Harb Mol Case Stud
; 5(2)2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30936194
14.
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.
Lung Cancer
; 108: 205-211, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28625636
15.
Consumptive coagulopathy in angiosarcoma: a recurrent phenomenon?
Sarcoma
; 2014: 617102, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24693222
16.
Activity of Sorafenib against desmoid tumor/deep fibromatosis.
Clin Cancer Res
; 17(12): 4082-90, 2011 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21447727
17.
Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor).
Cancer
; 116(9): 2258-65, 2010 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20187095